<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg"/></p>
<p>佩維福斯科維鈉是一種潛在的首創衣殼組裝調節劑，正在開發用於治療慢性乙型肝炎病毒（HBV）。圖片來源：Jarun Ontakrai / Shutterstock.com。</p>
<p>Aligos Therapeutics 與廈門安默拓生物科技簽署了獨家許可協議，旨在為大中華區的慢性乙型肝炎病毒（HBV）感染開發和商業化佩維福斯科維鈉。</p>
<p>該地區包括香港、澳門、中國大陸和台灣。合作的重點是滿足該地區超過 9000 萬受 HBV 影響人羣的需求。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>乙型肝炎病毒感染 - 全球藥物預測和市場分析...</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據協議，Aligos 將獲得 2500 萬美元的前期里程碑付款。</p>
<p>該公司仍有資格獲得高達 4.2 億美元的額外臨牀、監管和銷售里程碑付款，以及在安默拓許可區域的淨銷售額中分級的高個位數特許權使用費。</p>
<p>Aligos 保留在大中華區以外的佩維福斯科維鈉開發和商業化活動的所有權利，特別是在歐洲、日本、韓國和美國，並將在大中華區進行臨牀試驗。</p>
<p>根據現有的運營計劃，該公司預計此交易將延續其當前的現金、現金等價物和投資至 2026 年第四季度。</p>
<p>佩維福斯科維鈉是一種潛在的首創衣殼組裝調節劑（CAM-E），正在開發用於治療慢性 HBV。</p>
<p>目前正在進行 II 期 B-SUPREME 研究，比較其與替諾福韋二吡呋酯（TDF）的療效。第二次中期分析預計將在 2026 年下半年進行，最終的頂線數據預計在 2027 年發佈。</p>
<p>廈門安默拓生物科技董事長兼首席執行官孫力表示：“Aligos 處於 HBV 創新的前沿，我們很高興能與這個傑出的團隊深化合作。我們相信佩維福斯科維鈉有潛力改變慢性 HBV 的抑制，我們為能夠在大中華區許可這一重要項目感到自豪。</p>
<p>“隨着我們繼續構建我們的產品組合，包括與 Aligos 合作的 ASO 和已批准的 PEGBING 療法，我們期待探索能夠為該地區患者帶來實質性益處的組合方案。”</p>
<p>協議的簽署預計將在 30 天內完成，需經廈門安默拓生物科技股東批准。</p>

ALGS

美國制藥 ETF - iShares

基因改革 ETF - ARK

<p>Aligos Therapeutics 已與廈門安默拓生物科技簽署獨家許可協議，以開發和商業化用於慢性 HBV 感染的佩維福斯可維鈉，適用於大中華區，包括香港、澳門、 mainland China 和台灣。Aligos 將獲得 2500 萬美元的預付款，並有可能獲得高達 4.2 億美元的額外里程碑付款。該藥物目前正在進行第二階段臨牀試驗，預計最終數據將在 2027 年公佈。該協議需經股東批准，預計將在 30 天內完成</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-17-04-2026-shutterstock_679733212-430x241.jpg"/></p>
<p>Pevifoscorvir sodium is a potential first-in-class capsid assembly modulator being developed to treat chronic HBV. Credit: Jarun Ontakrai / Shutterstock.com.</p>
<div class="lb-trans"><p>佩維福斯科維鈉是一種潛在的首創衣殼組裝調節劑，正在開發用於治療慢性乙型肝炎病毒（HBV）。圖片來源：Jarun Ontakrai / Shutterstock.com。</p>
</div><p>Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.</p>
<div class="lb-trans"><p>Aligos Therapeutics 與廈門安默拓生物科技簽署了獨家許可協議，旨在為大中華區的慢性乙型肝炎病毒（HBV）感染開發和商業化佩維福斯科維鈉。</p>
</div><p>This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by HBV in this region.</p>
<div class="lb-trans"><p>該地區包括香港、澳門、中國大陸和台灣。合作的重點是滿足該地區超過 9000 萬受 HBV 影響人羣的需求。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>Hepatitis B Virus Infection - Global Drug Forecast and Market Analy...</h4>
<div class="lb-trans"><h4>乙型肝炎病毒感染 - 全球藥物預測和市場分析...</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/globaldata_marketing_solutions_logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Under the agreement, Aligos will receive an upfront milestone payment of $25m.</p>
<div class="lb-trans"><p>根據協議，Aligos 將獲得 2500 萬美元的前期里程碑付款。</p>
</div><p>The company remains eligible to receive up to $420m in additional clinical, regulatory, and sales milestones, along with tiered, high single-digit royalties on net sales in Amoytop’s licensed areas.</p>
<div class="lb-trans"><p>該公司仍有資格獲得高達 4.2 億美元的額外臨牀、監管和銷售里程碑付款，以及在安默拓許可區域的淨銷售額中分級的高個位數特許權使用費。</p>
</div><p>Aligos retains all rights for the development and commercialisation activities of pevifoscorvir sodium outside of Greater China, specifically in Europe, Japan, South Korea, and the US, and will conduct clinical trials in Greater China.</p>
<div class="lb-trans"><p>Aligos 保留在大中華區以外的佩維福斯科維鈉開發和商業化活動的所有權利，特別是在歐洲、日本、韓國和美國，並將在大中華區進行臨牀試驗。</p>
</div><p>The company expects this deal to extend its current cash, cash equivalents, and investments into the fourth quarter of 2026, based on its existing operating plan.</p>
<div class="lb-trans"><p>根據現有的運營計劃，該公司預計此交易將延續其當前的現金、現金等價物和投資至 2026 年第四季度。</p>
</div><p>Pevifoscorvir sodium is a potential first-in-class capsid assembly modulator (CAM-E) being developed to treat chronic HBV.</p>
<div class="lb-trans"><p>佩維福斯科維鈉是一種潛在的首創衣殼組裝調節劑（CAM-E），正在開發用於治療慢性 HBV。</p>
</div><p>It is being assessed in the Phase II B-SUPREME study at present, which compares it to tenofovir disoproxil fumarate (TDF). The second interim analysis is expected during the second half of 2026, with final top line data anticipated in 2027.</p>
<div class="lb-trans"><p>目前正在進行 II 期 B-SUPREME 研究，比較其與替諾福韋二吡呋酯（TDF）的療效。第二次中期分析預計將在 2026 年下半年進行，最終的頂線數據預計在 2027 年發佈。</p>
</div><p>Xiamen Amoytop Biotech chairman and CEO Sun Li said: “Aligos is at the forefront of HBV innovation, and we are pleased to deepen our partnership with this outstanding team. We believe pevifoscorvir sodium has the potential to transform chronic HBV suppression, and we are proud to license this important programme for Greater China.</p>
<div class="lb-trans"><p>廈門安默拓生物科技董事長兼首席執行官孫力表示：“Aligos 處於 HBV 創新的前沿，我們很高興能與這個傑出的團隊深化合作。我們相信佩維福斯科維鈉有潛力改變慢性 HBV 的抑制，我們為能夠在大中華區許可這一重要項目感到自豪。</p>
</div><p>“As we continue to build our portfolio, including the Aligos-partnered ASO and approved PEGBING therapy, we look forward to exploring combination approaches that deliver meaningful benefits to patients across the region.”</p>
<div class="lb-trans"><p>“隨着我們繼續構建我們的產品組合，包括與 Aligos 合作的 ASO 和已批准的 PEGBING 療法，我們期待探索能夠為該地區患者帶來實質性益處的組合方案。”</p>
</div><p>Closing of the agreement is expected within 30 days, subject to Xiamen Amoytop Biotech shareholder approval.</p>
<div class="lb-trans"><p>協議的簽署預計將在 30 天內完成，需經廈門安默拓生物科技股東批准。</p>
</div>

Aligos 與廈門艾美拓簽署 HBV 治療協議